Cynapsus Therapeutics Inc. (CYNA)

[scottsmith]

Big shoutout to noretreat. Between this and rdhl you making me good $$$ this year.

[scottsmith]

Boom!

[CHM_760]

Sunovion Pharmaceuticals to Acquire Cynapsus Therapeutics - $40.50/share

http://www.businesswire.com/news/home/20160831006494/en

Hallalujah!

[noretreat]

From the company website:



Cynapsus Receives FDA Fast Track Designation for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson’s Disease

August 29, 2016
Company provides timing updates

TORONTO, Aug. 29, 2016 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc. (NASDAQ:CYNA) (TSX:CTH), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for APL-130277, a product candidate for the treatment of OFF episodes in patients with Parkinson’s disease (PD).

“The FDA’s recognition of the significant need to address OFF episodes in Parkinson’s disease with the Fast Track Designation is further validation of the value in our fast-acting, thin strip approach,” said Anthony Giovinazzo, President and CEO of Cynapsus. “We look forward to continuing to work with the FDA to advance APL-130277 through the regulatory process to bring relief to patients suffering with OFF episodes as expeditiously as possible. Our Phase 3 clinical program is nearing completion and we plan to submit a new drug application (NDA) to the FDA in the first half of 2017.”

FDA's Fast Track Designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and with the potential to address an unmet medical need. Companies that receive Fast Track Designation are provided the opportunity for more frequent interactions with FDA during clinical development and are potentially eligible for accelerated approval and/or priority review, if relevant criteria are met. Additionally, companies that receive Fast Track Designation may be allowed to submit completed sections of their NDA for the drug on a rolling basis, resulting in the potential for an expedited FDA review process.

In addition, Cynapsus provided timing updates for two clinical trials. Based on patient visit schedules, post the dose titration phase, top line data for the Phase 3 Efficacy trial CTH-300 is expected in mid-to-late fourth quarter of 2016. Furthermore, the CTH-201 Phase 2 Thorough QT study, is expected to commence in the fourth quarter of 2016, and is planned to be completed in the first half of 2017.

[noretreat]

BRIEF-Cynapsus receives fda fast track designation for APL-130277
REUTERS 5:36 AM ET 8/29/2016
Aug 29 (Reuters) - Cynapsus Receives FDA fast track designation for apl

* 130277 for the treatment of off episodes in patients with Parkinson's disease

* Cynapsus receives FDA fast track designation for APL-130277 for the treatment of off episodes in patients with Parkinson's disease

* Says we plan to submit a new drug application (NDA) to FDA in first half of 2017

* Post dose titration phase, top line data for phase 3 efficacy trial CTH-300 is expected in mid-to-late Q4 of 2016

* CTH-201 phase 2 thorough QT study, is expected to commence in Q4 of 2016, and is planned to be completed in first half of 2017 Source text for Eikon: Further company coverage:

(c) Copyright Thomson Reuters 2016. Click For Restrictions - about.reuters.com/fulllegal.asp

[scottsmith]

PR this morning: Granted Fast Track by FDA.

[scottsmith]

Back in this sturdy vessel. Let the fast $$ and dreamers hunt elsewhere.

[Rob_]

Whoops. I didn't relaize there were so many options and warrants. I just checked the share count on yahoo before I posted. Beginners mistake. Thats why I don't post much. Only been invested in CYNA for a little over two years, but things are looking good.

[noretreat]

Most of my shares are in my 401k. Fortunately. But I'm still hoping to pay a lot of tax.

[Fortytwo]

Fortunately in Canada we have a Tax Free Savings Account. All the upside is tax free! (No deducting the downside though).

[noretreat]

Same here. Big tax bill coming up! Probably next year.

[Fortytwo]

Fully diluted, approx 16 million shares. $30 equals $500 million market cap. $60 equals $ 1 billion market cap.
Should land at $45 minimum when dust settles. Following and invested heavily for 6 years.

[Rob_]

I am not going to venture a guess, but I think the company should have at least a $500M market capitalization (~$40 per share) after a successful phase 3 and filed NDA. $30 by the end of the year would be great though.

I think the company wants to be bought out and $60 per share (over $700M market cap) sounds good to me, but I would definitely accept more.

[kinyiose]

CYNA is worth bout $60. I believe $30 is the Price target for after topline phase 3 news is released next month.

[CHM_760]

BMO Capital Markets reiterated their "Buy" rating yesterday, and raised the price target from $25 to $30.

Hopefully just the beginning...

[TheMonolith]

Looks like the great rise has begun!

[Rob_]

$30 is a market cap of only $370 million (if my math is correct - based on 12.3M shares). I think CYNA's drug is more valuable than that.

[someconcerns]

All buckled in.

[noretreat]

another new high ... $19.40. $30 is coming!

[noretreat]

New high. Enjoy the ride up, as it is just getting going.

[noretreat]

See today's post: 3 bullet points from the Journal of Movement Disorders. Not MY opinion....simply fact!

[noretreat]

Published: Cynapsus Therapeutics announces publication in journal Movement Disorders of data for treatment of OFF episodes in patients with parkinson's disease
REUTERS 5:20 AM ET 8/12/2016

Aug 12 (Reuters) - Cynapsus Therapeutics Inc(CYNA) :

* APL-130277 was safe and generally well-tolerated with no discontinuations because of adverse events

* Announces publication in journal Movement Disorders of data for treatment of OFF episodes in patients with parkinson's disease

* Results suggests APL-130277 rapidly and effectively converts patients from off to full on state Source text for Eikon: Further company coverage:

[TheMonolith]

Can you give me your 3 Bullet points why your compelled by that statement?

I love the dip fake this spring and otherwise sideways action. What are the upcoming catalyst to launch it and when expect?

Been busy. Check my profile for some good picks. That's how I found cyna, through you.

[noretreat]

At some point it should run to 30+. Where have you been?

[TheMonolith]

Bout to explode?

[CHM_760]

Cynapsus Therapeutics Announces Positive Phase 3 Dose Titration Phase Results with APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease

webcast tomorrow at the delightful hour of 7:30am ET

http://ir.cynapsus.ca/press-releases/detail/158

[noretreat]

this still looks like a big winner through year-end and into next year.

[hogfan2]

$CYNA After holding the same stake for one year, Samuel Isaly raised stake by 400k to hold 1.6mln sh 13.2% as of 7/6 https://hedgemind.com/real-time-insights/stock-holdings?ticker=CYNA …

[coinguy]

Amended Statement of Ownership, Looks like OrbiMed Capital Just picked up 480,000 more shares. Very nice

[noretreat]

I'm guessing there will be a few escalating doses in the NDA based on severity and/or disease progression and/or responsiveness to the therapy.

[noretreat]

didn't really slip in my view.

[kris_kade]

Why are they indicating dose titration study to be part of P3 read out ? Company still not fixed the optimal dosage then ? Bit confusing

[kris_kade]

Timeline slipped to 3q end. Any reason co shared ? Thanks

[noretreat]

This is going to $30 by the end of the year

[noretreat]

Cynapsus Therapeutics Enrolls Last Patient in Pivotal Phase 3 Efficacy Trial of APL-130277 to Treat OFF Episodes in Patients with Parkinson’s DiseaseDose titration phase results expected in mid to late July with top-line results expected near the end of Q3 2016
GLOBENEWSWIRE 5:00 AM ET 6/30/2016

TORONTO, June 30, 2016 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc.(CYNA) , a specialty central nervous system (CNS) pharmaceutical company developing and preparing to commercialize APL-130277, a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with Parkinson’s disease (PD), announced today that the last patient has been enrolled in its pivotal Phase 3 efficacy study, CTH-300. Dose titration phase results from this study are expected in mid to late July and top-line data are expected to be released near the end of the third quarter of 2016.


The CTH-300 trial is a double-blind, placebo-controlled, parallel-design study with PD patients who have at least one OFF episode every 24 hours, with total OFF time of at least two hours per day. The study objective is to evaluate the efficacy and safety of APL-130277 versus placebo in patients with PD. Patients will each be observed for 12 weeks, with dosing at home and in clinic. The primary endpoint is mean change in the Movement Disorder Society’s Unified Parkinson’s Disease Rating Scale Part III score at 30 minutes after dosing in the clinic at week 12. The key secondary endpoint will be the percentage of patients who convert from the OFF to the ON state at or before 30 minutes of dosing with APL-130277 at the week 12 visit.

About Parkinson’s Disease and OFF Episodes

More than 1 million people in the U.S. and an estimated 4 to 6 million people worldwide suffer from Parkinson's disease. Parkinson’s disease is a chronic, progressive neurodegenerative disease that impacts motor activity, and its prevalence is increasing with the aging of the population. OFF episodes are a complication of Parkinson’s disease characterized by motor symptoms, including tremor at rest, rigidity and impaired movement, as well as significant non-motor symptoms such as cognitive impairment and mood disorders. An estimated one quarter to one half of all people with Parkinson’s disease whose symptoms are otherwise managed with ongoing drug therapy experience OFF episodes at least once daily and up to six times daily, with each episode lasting between 30 and 120 minutes.

About Cynapsus

Cynapsus is a specialty CNS pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with PD. The Company successfully completed a Phase 2 clinical trial for its product candidate, APL-130277, a sublingual formulation of apomorphine hydrochloride, or apomorphine. Apomorphine is the only molecule approved for acute, intermittent treatment of OFF episodes for advanced PD patients, but is currently only approved as a subcutaneous injection in the United States. APL-130277 is a “turning ON” medication designed to rapidly, safely and reliably convert a PD patient from the OFF to the ON state while avoiding many of the issues associated with subcutaneous delivery of apomorphine. It is designed to convert all types of OFF episodes, including morning OFF episodes, often considered the most difficult to treat. Cynapsus’ Phase 3 clinical program for APL-130277 plans to rely on the abbreviated Section 505(b)(2) regulatory pathway in the United States, and the company intends to submit an NDA near the end of 2016 or in early 2017. For additional company information, please visit our website www.cynapsus.ca. For more information about the Phase 3 studies please visit the website http://cth300and301trials.cynapsus.ca/

Forward-Looking Statements

This announcement contains "forward-looking statements" within the meaning of applicable securities laws, including, without limitation, the anticipated timing, completion and results of Phase 3 and other clinical studies; the Company’s expectation for filing an NDA near the end of 2016 or in early 2017; and beliefs related to potential benefits and effectiveness of Cynapsus’ product candidate. These forward-looking statements include information about possible or assumed future results of the Company’s business, financial condition, results of operations, liquidity, plans and objectives. In some cases, you can identify forward-looking statements by terminology such as “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. These forward-looking statements are based on the Company’s current expectations and beliefs and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ from those anticipated in such forward-looking statements as a result of risks and uncertainties, and include, but are not limited to, those factors identified under the caption “Risk Factors” in the Company’s Form 10-K filed with the United States Securities and Exchange Commission (the “SEC”) on March 9, 2016, as amended by Amendment No. 1 to Form 10-K/A filed with the SEC on March 18, 2016, and its other filings and reports in the United States with the SEC available on the SEC’s web site at www.sec.gov, and in Canada with the various Canadian securities regulators, which are available online at www.sedar.com. Furthermore, unless otherwise stated, the forward-looking statements contained in this press release are made as of the date of this press release, and the Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, changes or otherwise, except as required by law.

Neither the NASDAQ nor the TSX has approved or disapproved of the contents of this press release.

Contact Information

Company Contact:
Kristen Galfetti
Vice President, Investor Relations
[phone] x246
[e-mail]

Media Contact:
Russo Partners LLC
Matt Middleman
[phone]
[e-mail]
Source: Cynapsus Therapeutics Inc.(CYNA)
2016 GlobeNewswire, Inc.

[noretreat]

Tried to buy during the dip but could not get any quantity...but did add a few.

[noretreat]

TORONTO, June 21, 2016 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc.(CYNA) , a specialty central nervous system (CNS) pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with Parkinson’s disease (PD), announced that seven posters will be presented today at the 20th International Congress of Parkinson’s Disease and Movement Disorders (ICPDMD) Annual Meeting in Berlin.

The following data will be presented today:

New Poster Presentations

1. Physician Primary Research Insights – Holly Shill, M.D. (Poster #836)

APL-130277 dose needed to convert patients to Full ON from OFF state not correlated with commonly used measures
Disease severity not predictive of APL-130277 dose required to convert a PD patient from OFF to Full ON
Data supports titrating patients from lowest available APL-130277 dose

2. Patient/Caregiver Primary Research Insights - Eric J. Pappert, M.D. (Poster #837)

Over 30% of patients and caregivers reported OFF episodes in first year post diagnosis
An additional 53% indicated OFF episodes commenced 2-3 years post diagnosis
Patients and caregivers believe that OFF episodes have a negative impact on Quality of Life
Patients are open to new treatments

3. Treatment of OFF Episodes: An Evaluation of Physician Practices - Eric J. Pappert, M.D. (Poster #838)

Physicians are concerned about OFF episodes in the management of Parkinson’s disease
Physicians report their patients are aware of OFF episodes
Physicians believe there is a high unmet need for new treatment options for OFF episodes

4. Hamster Mucosal Toxicology Study of APL-130277 - Albert Argo, Ph.D. (Poster #846)

APL-130277 produced no irritation of the cheek pouch when administered at a relatively high dose
Encore Poster Presentations

5. Efficacy of APL-130277 to Convert OFF to Full ON by Demographics and Baseline Disease Characteristics - Holly Shill, M.D. (Poster #848)

APL-130277 converts patients with PD from OFF to Full ON, regardless of demographics or disease characteristics

6. PK/PD of APL-130277 - Eric J. Pappert, M.D. (Poster #850)

On average, a minimum apomorphine plasma concentration of 2.64 ng/ml was needed to turn a patient to Full ON from the OFF state
Plasma levels above this minimum efficacious concentration resulted in sustained improvements in motor function and ON time
Responders had large, clinically meaningful Movement Disorder Society’s Unified Parkinson’s Disease Rating Scale Part III (MDS-UPDRS III) changes at all time-points while the non-responders had some motor improvement, but not enough to convert from OFF to Full ON

7. CTH-105: Change for ON - Holly Shill, M.D. (Poster #851)

A MDS-UPDRS III improvement of over 10 points and a change of 20% at 15 minutes post-APL-130277 dose was needed to turn a PD patient from the morning OFF state to Full ON
The posters will be accessible from Cynapsus’ corporate website at www.cynapsus.ca.

“These data presented at ICPDMD complement Cynapsus’ positive results shared at prior medical meetings and demonstrate an encouraging clinical profile and further support the potential opportunity that APL-130277 may have in effectively treating OFF episodes in patients with Parkinson’s disease.” said Albert Agro, PhD, chief medical officer of Cynapsus. “In addition, data support our belief that there exists a high unmet need, that physicians are concerned about the lack of adequate treatments for OFF episodes and that patients are open to new treatment options. We expect to share additional clinical data from our pivotal Phase 3 efficacy trial by the end of the third quarter of 2016 and anticipate using these data to file our new drug application near the end of 2016 or in early 2017.”

Cynapsus Sponsored Symposium

Cynapsus also hosted a satellite symposium at ICPDMD. Additional information can be found below and at the website link: http://www.mdscongress2016.org/

Title: From OFF to ON – Treating Levodopa-Induced OFF Periods in Patients with Parkinson’s Disease

The symposium was held on Sunday, June 19, 2016 and included discussions on the treatment of motor fluctuations and OFF episodes in Parkinson’s Disease. Participants included C. Warren Olanow, Fabrizio Stocchi, Anthony Schapira and Karl Kieburtz.

About Cynapsus

Cynapsus is a specialty CNS pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with PD. The Company has successfully completed a Phase 2 clinical trial for its product candidate, APL-130277, a sublingual formulation of apomorphine hydrochloride, or apomorphine. Apomorphine is the only molecule approved for acute, intermittent treatment of OFF episodes for advanced PD patients, but is currently only approved as a subcutaneous injection in the United States. APL-130277 is a “turning ON” medication designed to rapidly, safely and reliably convert a PD patient from the OFF to the ON state while avoiding many of the issues associated with subcutaneous delivery of apomorphine. It is designed to convert all types of OFF episodes, including morning OFF episodes, often considered the most difficult to treat. Cynapsus has initiated its Phase 3 clinical program for APL-130277, relying on the abbreviated Section 505(b)(2) regulatory pathway in the United States, and the Company intends to submit a new drug application near the end of 2016 or in early 2017. For additional company information, please visit our website www.cynapsus.ca. For more information about the Phase 3 studies, including enrollment criteria, please visit the website found here http://cth300and301trials.cynapsus.ca/

Forward-Looking Statements

This announcement contains "forward-looking statements" within the meaning of applicable securities laws, including, without limitation, the Company’s expectation for filing an NDA near the end of 2016 or in early 2017; expectations regarding the Company’s clinical and regulatory activities, including without limitation, the anticipated timing, completion and results of Phase 3 and other clinical studies; and beliefs related to potential benefits and effectiveness of, and demand for, our product candidate. These forward-looking statements include information about possible or assumed future results of the Company’s business, financial condition, results of operations, liquidity, plans and objectives. In some cases, you can identify forward-looking statements by terminology such as “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. These forward-looking statements are based on the Company’s current expectations and beliefs and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ from those anticipated in such forward-looking statements as a result of risks and uncertainties, and include, but are not limited to, those factors identified under the caption “Risk Factors” in the Company’s Form 10-K filed with the United States Securities and Exchange Commission (the “SEC”) on March 9, 2016, as amended by Amendment No. 1 to Form 10-K/A filed with the SEC on March 18, 2016, and its other filings and reports in the United States with the SEC available on the SEC’s web site at www.sec.gov, and in Canada with the various Canadian securities regulators, which are available online at www.sedar.com. Furthermore, unless otherwise stated, the forward-looking statements contained in this press release are made as of the date of this press release, and the Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, changes or otherwise, except as required by law.

Neither the NASDAQ nor the TSX has approved or disapproved of the contents of this press release.




Contact Information

Company Contact:
Kristen Galfetti
Vice President, Investor Relations
[phone] x246
[e-mail]

Media Contact:
Russo Partners LLC
Matt Middleman
[phone]
[e-mail]
Source: Cynapsus Therapeutics Inc.(CYNA)

[noretreat]

Just another analyst report...PT of $24 from Janney Capital

Its 'bout time this thing gets back near 20 bucks. As soon as the P3 results come in it will be 30+

[F1ash]

Boy today is a good day. Did I miss anything?

[noretreat]

New $24 Target Price from Janney Capital.

TOO LOW!

I think Merrill-Lynch has it pegged better at $33

[noretreat]

there just aren't many shares available. this thing could easily rise 50% with some buying interest.

of course, i wish i had loaded up even more in the $11 range, but i have a fair sized position

[F1ash]

Certainly seems to be near a pivotal level right here from looking back at the chart. Do you feel like the low volume could amplify a move in either direction.

[noretreat]

Higher highs and higher lows lately. Would be nice to see this back around 18 coming into the second half. Awareness of this may be starting to increase....

[CHM_760]

Cynapsus Therapeutics Announces Data Presentations at the European Academy of Neurology Annual Meeting

Presentations include positive preclinical toxicology results, quality-of-life data and physician OFF episode treatment practices

TORONTO, May 30, 2016 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics, Inc. (NASDAQ:CYNA) (TSX:CTH), a specialty central nervous system (CNS) pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with Parkinson’s disease (PD), today announced that three clinical posters will be presented today at the 2nd Congress of the European Academy of Neurology (EAN) Annual Meeting, in Copenhagen.

The following data will be presented by Eric J. Pappert, M.D., Vice President Global Medical Affairs, Cynapsus Therapeutics, today from 12:30-13:15 p.m. CET.

Poster Presentations

Apomorphine Film (APL-130277) Produces No Buccal Mucosal Irritation: Results from a 28-Day Toxicology Study in Hamsters (Poster #31123)
28-day toxicology study in 16 hamsters
APL-130277, Cynapsus’ apomorphine film, produced no irritation of the cheek pouch buccal mucosal of male and female hamsters when administered at a dose of 2.08 mg (15 times higher than a 30 mg dose in a 60 kg human) three times daily for 28 consecutive days

Treatments of OFF Episodes in Parkinson’s Disease: An Evaluation of Physician Practices (Poster #31122)
Responses from 120 caregivers and patients on the impact of OFF episodes on quality of life (QoL) and satisfaction with current patient treatment
32.6% of patients and caregivers indicated that they had OFF episodes in the first year post diagnosis
53.3% of patients and caregivers indicating that OFF episodes started 2-3 years post diagnosis
Patients and caregivers reported that OFF episodes had a negative impact on QoL

The Treatment of OFF Episodes in Parkinson’s Disease: An Evaluation of Patient and Caregiver Insights (Poster #31121)
102 physicians who treat patients with PD were queried on their practices and attitudes regarding the treatment of OFF episodes
Physicians are concerned about OFF episodes and feel that their patients are aware of OFF episodes
Physicians feel that there is a fairly high level of unmet need regarding treatment options for OFF episodes

The posters will be accessible from Cynapsus’ corporate website at www.cynapsus.ca.

“We are pleased to share data demonstrating that the APL-130277 sublingual thin film produced no signs of mucosal irritation in hamsters at doses significantly higher than the highest dose planned for patients,” said Albert Agro, Ph.D., chief medical officer of Cynapsus. “These data, in addition to prior positive results shared at medical meetings, provide evidence of the potential safety of APL-130277 in treating OFF episodes. In addition, information gathered through extensive surveys we conducted supports our beliefs that physicians are concerned about OFF episodes and that there exists a high unmet need. Most importantly, survey results showed patients are open to new treatments that would result in an improved quality-of-life. We look forward to sharing clinical data from our pivotal Phase 3 efficacy trial over the next several months and anticipate using these data to file our new drug application (NDA) near the end of 2016 or in early 2017.”

Cynapsus also hosted a satellite symposium at EAN. Additional information can be found below and at the website link: https://www.eaneurology.org.

Cynapsus Sponsored Symposium

From OFF to ON – New approaches to the treatment of OFF episodes in Parkinson’s Disease

The symposium was held on Saturday, May 28, 2016, and included discussions on Levodopa-induced OFF episodes, approaches to the treatment of OFF episodes and rescue therapies. Participants included C. Warren Olanow, Fabrizio Stocchi and Anthony H.V. Scharpira.

[someconcerns]

NR, $30 in 12 months sounds mmm..mmmm good to me.

[noretreat]

I have all I need. Not buying or selling. I'm thinking around $30 in 12 months.

[someconcerns]

Encouraging price movement this morning. R U buying more now?

[coinguy]

I'm I correct that only Giovinazzo the CEO only owns 89K shares, not very much, and none of the Directors have any shares? But prefer cash(salary) instead. Which also is the case for all employees?
Seems very odd that no one, for the most part owns shares in the company that they work for?

[CHM_760]

$33 price objective, Merrill Lynch:
(credit to Zenka on IV board)

Merrill Lynch Has 3 Top BioPharma Picks to Win From the Aging of America

By Jon C. Ogg May 10, 2016 7:45 am EDT
Print Email
When investors hear the term “The Silver Economy,” some may think of the metal silver. Other investors think of this as the aging trends happening in the world. There are now, or will be soon, a record number of elderly and aging adults who need care of some sort. A Merrill Lynch report has a whole wave of companies featured as Global Ageing Primer Picks.

While much of the report targets how society is not prepared to deal with this tidal wave of the elderly, it also sees opportunity in several sectors. The firm sees a multi-trillion dollar opportunity in and around health care, financials, aged-care and consumer operations.

24/7 Wall St. decided to first focus on the biotech and pharmaceutical picks from the firm here. These companies are all rated as Buy at Merrill Lynch, and the firm assigned a “High” exposure to longevity. This implies that each one has ageing-related products, technologies, services and solutions as core to the business model, with a material amount of sales or growth being a driver.

ACADIA Pharmaceuticals

Besides being rated as Buy, ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) has a $40 price objective at Merrill Lynch. The firm also most recently covered ACADIA because Nuplazid was priced at a premium to other antipsychotic drugs for its June launch. The company expects a slow launch due to CNS drug prescription and patient trends.
24/7 Wall St.
10 Stocks to Own for the Decade

After receiving FDA approval for its Parkinson’s disease psychosis drug, at least some watchers think it could make for an attractive buyout target for a larger biotech or pharmaceuticals buyer.

ACADIA has a $3.3 billion market cap, and its $29.25 share price is against a 52-week trading range of $16.64 to $51.99.

Cynapsus Therapeutics

Merrill Lynch has a $33 price objective on Cynapsus Therapeutics Inc. (NASDAQ: CYNA), while the current share price is $12.18. This is obviously a speculative buy rating that gets very few research calls.

The company is a specialty central nervous system pharma outfit developing and preparing to commercialize a fast-acting sublingual thin film for the on-demand management of debilitating OFF episodes associated with Parkinson’s disease.

Cynapsus has a consensus analyst price target of $20.90 and a 52-week range of $10.54 to $18.50. Its market cap of $150 million classifies this in the highly speculative small-cap category with little to no significant revenues.

Radius Health

Radius Health Inc. (NASDAQ: RDUS) is also a Merrill Lynch Buy-rated speculative company with a “high” longevity exposure. Its $58.00 price objective was almost 75% above the $33.28 share price. Merrill Lynch’s most recent call was on May 5 and addressed a data display delay due to post-terror security issues in Belgium. The firm believes that Radius offers an attractive risk/reward profile for investors. The firm said:

The company’s lead pipeline asset, abaloparatide, should reach the U.S. and E.U. markets in 2016/2017 and could generate peak sales of roughly $1.5 billion.

Radius has a consensus analyst target of $59.83, and its 52-week range is $24.75 to $84.64.

By Jon C. Ogg

[noretreat]

Anywhere near here is a good entry, in my opinion. As long as P3 delivers the result will be a decent multiple.